Village Global is an early stage venture capital firm backed by some of the world's most successful entrepreneurs.

Village Global

Amplify Partners invests in technical founders solving technical problems for the enterprise. They invest in early-stage companies pioneering novel applications in machine intelligence and computer science.

Amplify Partners

TenOneTen Ventures is a venture capital firm that invests in start-ups that apply data and technology to disrupt existing industries.

TenOneTen Ventures

Stage Venture Partners is a seed venture capital firm that invests in emerging software technology for B2B markets. Founded in 2015 by two entrepreneurial partners, Stage is designed to deliver active, thoughtful investment and exceptional performance. One of us is a successful international operator who has built global businesses. The other is an experienced investor and venture capitalist with a strong track record. Stage VP invests in founders building cutting edge software technology for enterprise clients. Founders, especially those solving hard problems that matter, seek us out for our unique expertise, and our alignment with their daring vision. We have the conviction to be first; often the first institutional investor on the cap table and the first to identify new technological trends. We are not driven by thesis, geography, or sector. Instead, we seek out recurring revenue earned at the frontiers of what’s possible in enterprise software.  We believe we have the breadth to capitalize on investment opportunities across next-gen enterprise software, and the focus of a disciplined, expert investor.

Stage Venture Partners

We're an early stage venture capital firm focused on equity investments in companies with dramatic growth potential, primarily in technology and highly-scalable services businesses. Our focus investment areas are digital health, fintech, consumer software, and enterprise software.

OCA Ventures

Serra Ventures is a venture capital firm investing in technology companies throughout the U.S. and in select international locations. Sectors we focus on include information technology, devices/instrumentation and agricultural technologies.

Serra Ventures

Intel Capital invests in innovative startups targeting cloud and AI infrastructure, edge, 5G, autonomy, cybersecurity, client & gaming, enterprise applications, silicon design and manufacturing, and a wide range of other disruptive technologies.

Intel Capital

Susa Ventures is an early-stage venture capital firm investing primarily in seed rounds. The firm was founded in October 2013 and si headquartered in San Francisco, California, United States.

Susa Ventures

Loup Ventures is a research-driven venture capital firm based in Minneapolis and New York investing in frontier technology.

Loup Ventures

Twin Ventures is an AI-focused Angel Investors that builds and fosters AI-first startups. Twin Ventures backs entrepreneurs who are building disruptive ventures, solving real-world problems. The company invests in companies that define new markets that can turn into category leaders through Applied AI. Twin Ventures invests in startups at an early stage and acts as angel investors or pre-seed investors that offers a typical check size is $100,000 with follow-on investments of up to $150,000.

Twin Ventures

Morpheus is a venture capital firm that invests in consumer to enterprise technologies including data analytics, machine learning, robotics, transportation, and SaaS. The firm was founded in 2016 and is headquartered in Los Angeles.

Morpheus Ventures

Debiopharm Innovation Fund invests in digital health companies that have an impact on cancer, infectious diseases, and drug development. We are looking for ambitious entrepreneurs raising series A or B with clinically proven, transformative technologies that use AI and data to help patients. We do not invest in consumer wellness or workflow solutions. Our initial investment is typically $2-5M. Along with capital we bring deep pharma knowledge & networks and long-term commitment to help build value in your company. We are an evergreen investment fund of the pharmaceutical company Debiopharm based in Lausanne, Switzerland.

Debiopharm Innovation Fund

VeriSIM Life

VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials. VeriSIM offers a range of translational-based solutions, customized for the pre-clinical and clinical programs. These offerings are all centered around their proven and validated BIOiSIMTM platform for small molecules, large molecules, and viruses.

VeriSIM Life is an AI-powered drug discovery company offering a machine learning-driven platform, BIOiSIM, which allows pharmaceutical companies and drug developers to conduct preclinical experiments using biosimulation models that reflect interactions between drugs and animals' biological systems. The platform can predict a potential drug’s response and clinical outcome without the need for actual animal testing, thereby reducing the cost and time spent on animal trials or even entirely eliminating them.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Can AI increase the pace and quality of pharmaceutical research? VeriSIM Life says yes

Mayo Clinic

VeriSIM Life has partnered with Mayo Clinic to accelerate the development of novel drugs for a variety of therapeutic areas including oncology, hematology, and neurology.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

VeriSIM Life is an AI-powered drug discovery company offering a machine learning-driven platform, BIOiSIM, which allows pharmaceutical companies and drug developers to conduct preclinical experiments using biosimulation models that reflect interactions between drugs and animals' biological systems. The platform can predict a potential drug’s response and clinical outcome without the need for actual animal testing, thereby reducing the cost and time spent on animal trials or even entirely eliminating them.The company is also engaged in developing novel therapeutics through its subsidiary PulmoSIM Therapeutics, which leverages the BIOiSIM platform. PulmoSIM has two drug candidates in its pipeline targeting pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), both of which are in their preclinical stages. VeriSIM Life acquired Spanish biotechnology firm <a href="https://sp-edge.com/updates/10359">Molomics Biotech </a>in May 2022, to integrate VeriSIM’s platform with Molomics’ Human Collective Intelligence (HCI) technology, enhancing the company’s ability to make successful clinical trial predictions.In <a href="https://sp-edge.com/updates/28167">April 2024</a>, VeriSIM Life launched its AtlasGEN Novel Drug Designer, a platform that focuses on combining generative chemical discovery and biological validation to increase efficiency in drug candidate selection. It is part of the BIOiSIM platform that uses a unique Translational Index to give insights into the AI analysis and the potential effectiveness and safety of created compounds.

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

<div>
 
 Verge Genomics is a biotechnology company engaged in developing therapeutics for neurological diseases using human genomics and AI to accelerate drug discovery. The main target areas are Amyotrophic Lateral Sclerosis (ALS), Parkinson&rsquo;s Disease (PD), and Frontotemporal Dementia (FTD).&nbsp;
 
 
 It has built a proprietary all-human platform (unlike standard clinical trials that rely on animal data), called CONVERGE, that uses data sets from brain tissue samples of deceased patients with ALS and PD. While most drugs target only one gene at a time, the company claims its technology can identify hundreds of genes that cause disease and develop drugs that target all the genes at the same time. The company uses AI technology to optimize the drug discovery process as a whole.
 
 
 As of March 2024, Verge had one drug candidate in the clinical stage (Phase I) and 10 drug candidates in the discovery stage.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has partnerships with various tissue banks (such as Harvard University and University of Miami Miller School of Medicine) and several educational institutes and foundations (such as Target ALS, Answer ALS) that enabled its drug discovery platform.&nbsp;
 
 
 In addition, the company&rsquo;s customers include several pharmaceutical companies, such as 1) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-announces-research-collaboration-with-the-sheffield-institute-for-translational-neuroscience">
 Sheffield Institute for Translational Neuroscience (SITraN)
 </a>
 to accelerate the validation of novel drug targets and screening of drug compounds for Parkinson's disease (February 2021), 2) 
 <a href="https://sp-edge.com/updates/4146">
 Eli Lilly
 </a>
 to research and develop novel therapies to treat ALS (July 2021), 3) 
 <a href="https://sp-edge.com/updates/21707">
 Alexion
 </a>
 to identify novel drug targets for rare neurodegenerative and neuromuscular diseases (September 2023), and 4) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-and-the-pritzker-neuropsychiatric-disorders-research-consortium-form-cutting-edge-schizophrenia-research-collaboration">
 Pritzker Neuropsychiatric Disorders Research Consortium
 </a>
 to analyze data from schizophrenic patient&rsquo;s brain tissue with Verge&rsquo;s technology (October 2023).
 
 
 Funding and financials
 
 
 In December 2021, Verge raised USD 98 million in an oversubscribed 
 <a href="https://sp-edge.com/updates/7426">
 Series A
 </a>
 funding round led by BlackRock. The funds were used to scale up its pre-clinical and clinical candidate programs in the pipeline and enhance its lead therapeutics through clinical testing. 
 
</div>

Verge Genomics

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response.

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Includes companies that use GenAI as a core part of their product offering for drug discovery & development

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

PROMINENT_CATEGORY

<div>
California-based AI preclinical experiment company VeriSIM Life and UK-based analytics company Clarivate have extended their existing partnership (initially entered in <a href="https://sp-edge.com/updates/18034"> April 2023 </a> ) to launch VeriSIM Life Translational Index on Clarivate's Cortellis Drug Discovery Intelligence platform. The terms and financial details of the agreement have not been disclosed.
The new tool offers predictive insights into factors related to the development of drugs, such as bioavailability, clearance rates, toxicity, and first-in-human dose when combined with Clarivate's Cortellis Drug Discovery Intelligence.
The partnership aims to accelerate drug development, improve preclinical success rates, and help biotech and pharmaceutical companies manage risks more effectively using AI-enabled workflows.
</div> California-based AI preclinical experiment company VeriSIM Life and UK-based analytics company Clarivate have extended their partnership to launch VeriSIM Life Translational Index on Clarivate's Cortellis Drug Discovery Intelligence platform. The tool provides predictive insights into drug development factors and aims to accelerate drug development, improve preclinical success rates, and help manage risks using AI-enabled workflows.

VeriSIM Life

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless